Dr. Suven Bhattacharjee

Nayan Eye Centre, Kolkata, India.

1 article

Dr Suven Bhattacharjee is an eye surgeon, inventor and entrepreneur. He completed his MBBS & then Diploma and MS Ophthalmology with university Gold Medal from JIPMER, Pondicherry. He is a Diplomate of the National Board (DNB) of Examinations, New Delhi and fellow of Retina Foundation, Ahmedabad. He is a consultant at Nayan Eye Centre, Kolkata and the Founder of Med Invent Devices Pvt. Ltd. which is a startup with many awards. He holds international patents for his invention, the B-HEX Pupil Expander which has redefined pupil expansion in cataract surgery. It is superior to competition, easier for surgeons, safer for patients and economical for health care systems. He has been a Top Innovator & Gold Medalist at the DST - Lockheed Martin - India Innovation Growth Program 2016. He has received the AIOS Dr P Siva Reddy International Award, Col Rangachari Award for overall best paper, Sante Vision Award for best Cataract Paper, ASCRS best paper of session, AIOS International Hero Award, CS Reshmi Gold medal for best video and APACRS Video award. His videos are regularly selected to challenging cases symposia at ESCRS & ASCRS. His papers in JCRS and IJO have been the most read papers. He has been the Chief instructor at many Instruction courses at AAO, ASCRS, ESCRS, APACRS, APAO, WOC & AIOC.

  1. Articles 1 Apr 2021 12 min read

    Ten Tips for Phacoemulsification in Small Pupil

    Phacoemulsification in eyes with preoperative non-dilating pupil or with intraoperative miosis is fraught with complications [1,2]. The following tips will help understand the small pupil and optimize strategy to deliver better outcomes. 1. Every eye is an IFIS candidate; Reduce threshold for using Pupil expansion devices: Since its original association with tamsulosin intake, Intraoperative Floppy Iris Syndrome (IFIS) has been positively correlated with a plethora of risk factors which include: gender, age, hypertension, other a1-adrenergic receptor antagonists, finasteride, angiotensin II receptor inhibitors, benzodiazepines, antipsychotics, hypertension drugs and decreased dilated pupil diameter [1,3,4]. The risk of IFIS exists regardless of alpha antagonist treatment, in eyes with 7.0 mm or smaller pupil [5]. Hence, it would be prudent to consider every eye a potential IFIS candidate. Increased patient expectations, surgeon's desire to consistently deliver good outcomes, use of tor

    Dr. Suven Bhattacharjee